Skip to main
CNMD
CNMD logo

CONMED (CNMD) Stock Forecast & Price Target

CONMED (CNMD) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 21%
Buy 29%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Conmed Corp demonstrated solid financial performance with General Surgery sales increasing by 8.7% to $206.9 million, outperforming expectations, while Orthopedic Surgery sales rose by 2.4% to $139.0 million, also exceeding consensus estimates. The company achieved an improved operating margin of 18.6%, attributable to gross margin expansion and operational efficiencies, and is expected to continue this upward trend, with earnings per share anticipated to grow faster than revenues. Moreover, the gross margin saw a rise to 57.6%, indicating strong pricing power and cost management, despite challenges from supply chain issues.

Bears say

The financial outlook for Conmed Corp reflects a bear case scenario wherein revenue growth is anticipated to decelerate to 4% or less, primarily due to sluggish performance in AirSeal and Buffalo Filter sales, coupled with potential challenges from new product launches. Furthermore, management has guided for 2025 revenue and EPS projections that fall below consensus estimates, citing ongoing supply chain difficulties that are expected to exert pressure on operating margins. Additionally, anticipated reductions in revenue estimates for 2025 and 2026 underscore the company’s struggles with capital spending in hospitals and adverse currency effects, contributing to a negative sentiment surrounding the stock.

CONMED (CNMD) has been analyzed by 14 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 29% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CONMED and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CONMED (CNMD) Forecast

Analysts have given CONMED (CNMD) a Buy based on their latest research and market trends.

According to 14 analysts, CONMED (CNMD) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $91.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $91.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CONMED (CNMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.